Literature DB >> 28750568

Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.

Haitham Salem1,2, Teresa Pigott1, Xiang Y Zhang2, Cristian P Zeni3, Antonio L Teixeira1,2.   

Abstract

INTRODUCTION: Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered: The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert commentary: Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.

Entities:  

Keywords:  Tardive dyskinesia; antipsychotics; dopamine receptor blockers; movement disorders; neuroleptics; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28750568     DOI: 10.1080/14737175.2017.1361322

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

1.  Deep brain stimulation in Fragile X syndrome with tardive dystonia.

Authors:  Francesco Bove; Carla Piano; Anna Rita Bentivoglio; Pietro Chiurazzi; Tommaso Tufo
Journal:  Neurol Sci       Date:  2021-02-12       Impact factor: 3.307

Review 2.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

3.  A Study on Drug-Induced Tardive Dyskinesia: Orofacial Musculature Involvement and Patient's Awareness.

Authors:  Arunachalam M Anusa; Rooban Thavarajah; Dinesh Nayak; Elizabeth Joshua; Umadevi Krishnamohan Rao; Kannan Ranganathan
Journal:  J Orofac Sci       Date:  2019-01-02

Review 4.  Pharmacogenomic Biomarkers and Their Applications in Psychiatry.

Authors:  Heejin Kam; Hotcherl Jeong
Journal:  Genes (Basel)       Date:  2020-11-30       Impact factor: 4.096

Review 5.  Tardive Dyskinesia in Older Persons Taking Antipsychotics.

Authors:  Leslie Citrome; Stuart H Isaacson; Danielle Larson; Daniel Kremens
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-14       Impact factor: 2.570

6.  Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia.

Authors:  Koki Nagaoka; Takuya Nagashima; Nozomi Asaoka; Hiroki Yamamoto; Chihiro Toda; Gen Kayanuma; Soni Siswanto; Yasuhiro Funahashi; Keisuke Kuroda; Kozo Kaibuchi; Yasuo Mori; Kazuki Nagayasu; Hisashi Shirakawa; Shuji Kaneko
Journal:  JCI Insight       Date:  2021-05-24

7.  Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia.

Authors:  Stanley N Caroff; Fan Mu; Rajeev Ayyagari; Traci Schilling; Victor Abler; Benjamin Carroll
Journal:  BMC Psychiatry       Date:  2020-07-11       Impact factor: 3.630

8.  Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.

Authors:  Richard B Lipton; Joshua M Cohen; Sanjay K Gandhi; Ronghua Yang; Paul P Yeung; Dawn C Buse
Journal:  Neurology       Date:  2020-08-03       Impact factor: 11.800

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.